Skip to content

Study of HRO761 alone or in combination in cancer patients with specific DNA alterations called Microsatellite Instability-High or Mismatch Repair Deficiency

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-502314-93-00
Acronym
CHRO761A12101
Enrollment
192
Registered
2023-09-19
Start date
2024-02-05
Completion date
Unknown
Last updated
2025-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MSIhi or dMMR advanced unresectable or metastatic solid tumors

Interventions

None listed

Sponsors

Novartis Pharma AG
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

Belgium, France, Germany, Italy, Norway, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026